MacroGenics Inc

MGNX

NASDAQ. Currency in USD

5.82 -0.57 ( -8.92% )

Real time prices: December 19

Market Cap.
357.79M
Beta (5Y monthly)
2.09
Price/Earnings
-
EPS (TTM)
-3.10
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
421,172
1y Target Est.
11.40
Day's Range
5.79
-
6.40
52 Week's Range
2.13
-
12.79

Historical Summary

Performance
EPS growth
Share Buybacks

About MacroGenics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.macrogenics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
61.26M
Employees
427
Address
9704 Medical Center Drive, Rockville, MD, United States, 20850
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Latest news

Zacks.com featured highlights MacroGenics, NerdWallet and Euronav
Zacks.com featured highlights MacroGenics, NerdWallet and Euronav

MacroGenics, NerdWallet and Euronav have been highlighted in this Screen of The Week article.
By Zacks Investment Research - 8 weeks ago

Can MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?
Can MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of...
By Zacks Investment Research - 8 weeks ago

Buy These 3 Top Stocks for Solid Earnings Acceleration
Buy These 3 Top Stocks for Solid Earnings Acceleration

Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & Euronav (EURN) at the moment for...
By Zacks Investment Research - 8 weeks ago

MacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving Average
MacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving...
By Zacks Investment Research - 8 weeks ago

Here's How to Find Cheap Stocks Under $10 to Buy for December
Here's How to Find Cheap Stocks Under $10 to Buy for December

Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for...
By Zacks Investment Research - 8 weeks ago

$5 Million Bet On IAC? Check Out These 3 Stocks Insiders Are Buying
$5 Million Bet On IAC? Check Out These 3 Stocks Insiders Are Buying

Although US stocks closed mixed on Friday, there were a few notable insider trades. When...
By Benzinga - 9 weeks ago

7 Analysts Have This to Say About Macrogenics
7 Analysts Have This to Say About Macrogenics

Over the past 3 months, 7 analysts have published their opinion on Macrogenics (NASDAQ:MGNX) stock....
By Benzinga - 9 weeks ago

Expert Ratings for Macrogenics
Expert Ratings for Macrogenics

Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish...
By Benzinga - 9 weeks ago